Cargando…

Corrigendum: Comparative Analysis of G1P[8] Rotaviruses Identified Prior to Vaccine Implementation in Pakistan With Rotarix™ and RotaTeq™ Vaccine Strains

Detalles Bibliográficos
Autores principales:	Sadiq, Asma, Bostan, Nazish
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772951/ https://www.ncbi.nlm.nih.gov/pubmed/33391290 http://dx.doi.org/10.3389/fimmu.2020.625157

Ejemplares similares

Comparative Analysis of G1P[8] Rotaviruses Identified Prior to Vaccine Implementation in Pakistan With Rotarix™ and RotaTeq™ Vaccine Strains
por: Sadiq, Asma, et al.
Publicado: (2020)

A Cost Effectiveness and Capacity Analysis for the Introduction of Universal Rotavirus Vaccination in Kenya: Comparison between Rotarix and RotaTeq Vaccines
por: van Hoek, Albert Jan, et al.
Publicado: (2012)

Correction: A Cost Effectiveness and Capacity Analysis for the Introduction of Universal Rotavirus Vaccination in Kenya: Comparison between Rotarix and RotaTeq Vaccines
por: van Hoek, Albert Jan, et al.
Publicado: (2012)

Real-time RT-PCR assays to differentiate wild-type group A rotavirus strains from Rotarix(®) and RotaTeq(®) vaccine strains in stool samples
por: Gautam, Rashi, et al.
Publicado: (2014)

G2P[4]-RotaTeq Reassortant Rotavirus in Vaccinated Child, United States
por: Roy, Sunando, et al.
Publicado: (2015)

One-step multiplex real-time RT-PCR assay for detecting and genotyping wild-type group A rotavirus strains and vaccine strains (Rotarix® and RotaTeq®) in stool samples
por: Gautam, Rashi, et al.
Publicado: (2016)

Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study
por: Vesikari, Timo, et al.
Publicado: (2010)

Hospital bed occupancy for rotavirus and all cause acute gastroenteritis in two Finnish hospitals before and after the implementation of the national rotavirus vaccination program with RotaTeq®
por: Hartwig, Susanne, et al.
Publicado: (2014)

Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland
por: Hemming, Maria, et al.
Publicado: (2013)

The temporal relationship between RotaTeq immunization and intussusception adverse events in the Vaccine Adverse Event Reporting System (VAERS)
por: Geier, David A., et al.
Publicado: (2012)

Assessing bias in administrative database studies of RotaTeq vaccine completion due to exclusion of subjects with incomplete follow-up
por: Lanes, Stephan, et al.
Publicado: (2015)

Dual Recognition of Sialic Acid and αGal Epitopes by the VP8* Domains of the Bovine Rotavirus G6P[5] WC3 and of Its Mono-reassortant G4P[5] RotaTeq Vaccine Strains
por: Alfajaro, Mia Madel, et al.
Publicado: (2019)

The Lewis A phenotype is a restriction factor for Rotateq and Rotarix vaccine-take in Nicaraguan children
por: Bucardo, Filemón, et al.
Publicado: (2018)

Whole Genome Analysis of Selected Human Group A Rotavirus Strains Revealed Evolution of DS-1-Like Single- and Double-Gene Reassortant Rotavirus Strains in Pakistan During 2015–2016
por: Sadiq, Asma, et al.
Publicado: (2019)

Pharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (Rotarix™) in Developed Countries
por: Plosker, Greg L.
Publicado: (2012)

The human rotavirus vaccine Rotarix™ in infants: An integrated analysis of safety and reactogenicity
por: Buyse, Hubert, et al.
Publicado: (2014)

Immunogenicity of rotavirus vaccine (Rotarix(TM)) in infants with environmental enteric dysfunction
por: Mwape, Innocent, et al.
Publicado: (2017)

Magnitude of Rotavirus A and Campylobacter jejuni infections in children with diarrhea in Twin cities of Rawalpindi and Islamabad, Pakistan
por: Sadiq, Asma, et al.
Publicado: (2019)

Introduction of rotavirus vaccination in Palestine: An evaluation of the costs, impact, and cost-effectiveness of ROTARIX and ROTAVAC
por: Debellut, Frédéric, et al.
Publicado: (2020)

Molecular characterization of human group A rotavirus genotypes circulating in Rawalpindi, Islamabad, Pakistan during 2015-2016
por: Sadiq, Asma, et al.
Publicado: (2019)

Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial
por: Steele, Andrew Duncan, et al.
Publicado: (2012)

Comparative analysis of the Rotarix™ vaccine strain and G1P[8] rotaviruses detected before and after vaccine introduction in Belgium
por: Zeller, Mark, et al.
Publicado: (2017)

G3 and G9 Rotavirus genotypes in waste water circulation from two major metropolitan cities of Pakistan
por: Naqvi, Syeda Sumera, et al.
Publicado: (2020)

Effect of innate antiviral glycoproteins in breast milk on seroconversion to rotavirus vaccine (Rotarix) in children in Lusaka, Zambia
por: Mwila-Kazimbaya, Katayi, et al.
Publicado: (2017)

The evolving epidemiology of rotavirus A infection in Brazil a decade after the introduction of universal vaccination with Rotarix®
por: Carvalho-Costa, Filipe A., et al.
Publicado: (2019)

Review of Over 15 Years Postmarketing Safety Surveillance Spontaneous Data for the Human Rotavirus Vaccine (Rotarix) on Intussusception
por: Singh, Tina, et al.
Publicado: (2022)

Rotavirus Vaccine Demand in Pakistan
por: HUSSAIN, Aamir
Publicado: (2016)

Reactogenicity and safety of the human rotavirus vaccine, Rotarix™ in The Philippines, Sri Lanka, and India: A post-marketing surveillance study
por: Bravo, Lulu, et al.
Publicado: (2014)

Post-marketing safety surveillance conducted in Korea (2008–2013) following the introduction of the rotavirus vaccine, RIX4414 (Rotarix™)
por: Shin, Son Moon, et al.
Publicado: (2016)

Correction to: Review of Over 15 Years Postmarketing Safety Surveillance Spontaneous Data for the Human Rotavirus Vaccine (Rotarix) on Intussusception
por: Singh, Tina, et al.
Publicado: (2022)

Serologic response to porcine circovirus type 1 (PCV1) in infants vaccinated with the human rotavirus vaccine, Rotarix™: A retrospective laboratory analysis
por: Han, Htay Htay, et al.
Publicado: (2016)

Epidemiological trends for hospital admissions for acute rotavirus gastroenteritis in Belgium following the introduction of routine rotavirus vaccination and the subsequent switch from lyophilized to liquid formulation of Rotarix(™)
por: RAES, M., et al.
Publicado: (2016)

Lessons Learned from Long-Term Assessment of Rotavirus Vaccination in a High-Income Country: The Case of the Rotavirus Vaccine Belgium Impact Study (RotaBIS)
por: Standaert, Baudouin, et al.
Publicado: (2020)

1729. Literature Review to Identify Evidence of Secondary Transmission of ROTATEQ® (RV5) Vaccine Strains to Unvaccinated Subjects
por: Li, Yuanqiu, et al.
Publicado: (2023)

Evaluation of ROTARIX(®) Booster Dose Vaccination at 9 Months for Safety and Enhanced Anti-Rotavirus Immunity in Zambian Children: A Randomised Controlled Trial
por: Laban, Natasha Makabilo, et al.
Publicado: (2023)

Maternal and Infant Histo-Blood Group Antigen (HBGA) Profiles and Their Influence on Oral Rotavirus Vaccine (Rotarix(TM)) Immunogenicity among Infants in Zambia
por: Chauwa, Adriace, et al.
Publicado: (2023)

The Sustained Rotavirus Vaccination Impact on Nosocomial Infection, Duration of Hospital Stay, and Age: The RotaBIS Study (2005–2012)
por: Standaert, Baudouin, et al.
Publicado: (2016)

Medium- to Long-Term Impact of Rotavirus Vaccination on Hospital Care in Belgium: A 7-Year Follow-Up of the Rotavirus Belgium Impact Study (RotaBIS)
por: Standaert, Baudouin, et al.
Publicado: (2015)

T7 expression plasmids for producing a recombinant human G1P[8] rotavirus comprising RIX4414 sequences of the RV1 (Rotarix , GSK) vaccine strain
por: Philip, Asha A., et al.
Publicado: (2023)

Immunogenicity and safety of the diphtheria, pertussis, tetanus and inactivated poliovirus vaccine when co-administered with the human rotavirus vaccine (Rotarix) in healthy Japanese infants: a phase IV randomized study
por: Gillard, Paul, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1ncfmuq2lli2864u5ue3uu9up8